// App-Quantinova.ai

4062 : Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.

Researchers

Presenter

  • Charles S. Fuchs

Principal Investigators

  • Yung-Jue Bang

  • Maria Di Bartolomeo

  • Mario Mandala

  • Min-Hee Ryu

  • Lorenzo Fornaro

  • Tomasz Olesinski

  • Christian Caglevic

  • Hyun Cheol Chung

  • Kei Muro

  • Eray Goekkurt

  • Wasat Mansoor

  • Raymond S. McDermott

  • Einat Shacham-Shmueli

  • Xinqun Chen

  • S. Peter Kang

  • Carlos Alberto Mayo

  • Atsushi Ohtsu

  • Kohei Shitara

Medical Centers

  • Smilow Cancer Hospital at Yale-New Haven, New Haven, CT

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

  • Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • HOPE - Hamatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany

  • The Christie Hospital, Manchester, United Kingdom

  • Adelaide and Meath Hospital, Dublin, Ireland

  • Merck & Co., Inc., Kenilworth, NJ

  • National Cancer Center Hospital, Tokyo, Japan

Locations

  • Ireland

  • Japan

  • Italy

  • Poland

  • Germany

  • Turkey

  • United Kingdom

  • United States

  • Israel

  • Chile

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02370498

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved